SG11201610320RA - Topical application for an anti-hsv antibody - Google Patents

Topical application for an anti-hsv antibody

Info

Publication number
SG11201610320RA
SG11201610320RA SG11201610320RA SG11201610320RA SG11201610320RA SG 11201610320R A SG11201610320R A SG 11201610320RA SG 11201610320R A SG11201610320R A SG 11201610320RA SG 11201610320R A SG11201610320R A SG 11201610320RA SG 11201610320R A SG11201610320R A SG 11201610320RA
Authority
SG
Singapore
Prior art keywords
topical application
hsv antibody
hsv
antibody
topical
Prior art date
Application number
SG11201610320RA
Other languages
English (en)
Inventor
Michaela Arndt
Jürgen Krauss
Dirk JÄGER
Original Assignee
Heidelberg Immunotherapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Immunotherapeutics Gmbh filed Critical Heidelberg Immunotherapeutics Gmbh
Publication of SG11201610320RA publication Critical patent/SG11201610320RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087Herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201610320RA 2014-06-26 2015-06-25 Topical application for an anti-hsv antibody SG11201610320RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14174174 2014-06-26
PCT/EP2015/064378 WO2015197763A1 (en) 2014-06-26 2015-06-25 Topical application for an anti-hsv antibody

Publications (1)

Publication Number Publication Date
SG11201610320RA true SG11201610320RA (en) 2017-01-27

Family

ID=51032986

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201610320RA SG11201610320RA (en) 2014-06-26 2015-06-25 Topical application for an anti-hsv antibody

Country Status (14)

Country Link
US (2) US11267871B2 (ja)
EP (1) EP3160997B1 (ja)
JP (1) JP6649284B2 (ja)
KR (1) KR102622280B1 (ja)
CN (2) CN114306596A (ja)
AU (1) AU2015279212B2 (ja)
BR (1) BR112016030422A2 (ja)
CA (1) CA2950489C (ja)
ES (1) ES2843277T3 (ja)
NZ (1) NZ726168A (ja)
RU (1) RU2703903C2 (ja)
SG (1) SG11201610320RA (ja)
WO (1) WO2015197763A1 (ja)
ZA (1) ZA201607813B (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11643459B2 (en) 2016-03-11 2023-05-09 Scholar Rock, Inc. TGFβ1-binding immunoglobulins and use thereof
EP3566749A4 (en) * 2017-01-09 2020-09-23 Medshine Discovery Inc. THIAZOLE DERIVATIVE AND USES OF IT
EP3677677A4 (en) 2017-08-30 2021-09-22 KM Biologics Co., Ltd. MONOCLONAL ANTIBODY AGAINST HSV GB OR CORRESPONDING ANTIGEN BINDING FRAGMENT
WO2020041910A1 (es) * 2018-08-28 2020-03-05 Pontificia Universidad Catolica De Chile Anticuerpo monoclonal 14f5f6 o fragmento del mismo, que reconoce específicamente virus herpes simple 1 y 2
US20210347857A1 (en) * 2018-08-28 2021-11-11 Pontificia Universidad Catolica De Chile Monoclonal antibody 11b2c7 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2
KR20210141948A (ko) * 2019-03-19 2021-11-23 앨버트 아인슈타인 컬리지 오브 메디신 단순 헤르페스 바이러스 감염의 예방 및 치료를 위한 모노클로날 항체
EP4172195A1 (en) * 2020-06-29 2023-05-03 GlaxoSmithKline Biologicals S.A. Hsv gegi heterodimer antibodies
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2023166081A1 (en) * 2022-03-02 2023-09-07 Heidelberg Immunotherapeutics Gmbh Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
US20240083981A1 (en) * 2022-09-02 2024-03-14 United BioPharma, Inc. Treatment of herpes simplex virus infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1866895A (en) * 1994-01-04 1995-08-01 Scripps Research Institute, The Human monoclonal antibodies to herpes simplex virus and methods therefor
DE60031874D1 (de) * 1999-09-30 2006-12-28 Univ Washington Immunologisch relevante antigene aus herpes simplexvirus
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
WO2005011580A2 (en) * 2003-07-25 2005-02-10 Board Of Regents, The University Of Texas System Compositions and methods for herpes simplex prophylaxis and treatment
US6984492B2 (en) * 2003-09-05 2006-01-10 Talecris Biotherapeutics, Inc. Methods and compositions for treating herpes infections
WO2010129033A2 (en) 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
DK2248825T3 (da) * 2009-05-04 2013-01-02 Ribovax Biotechnologies Sa Antigenbindingsfragment af et antistof til anvendelse i behandling og diagnosticering af okulare sygdomme
EP2308895A1 (en) * 2009-10-01 2011-04-13 Universität Duisburg-Essen Anti-HSV antibody
CA2832738A1 (en) * 2011-04-08 2012-10-11 Duke University Herpes simplex virus

Also Published As

Publication number Publication date
CN114306596A (zh) 2022-04-12
ES2843277T3 (es) 2021-07-16
AU2015279212B2 (en) 2020-08-20
KR102622280B1 (ko) 2024-01-08
NZ726168A (en) 2022-05-27
US20220169705A1 (en) 2022-06-02
AU2015279212A2 (en) 2017-04-27
ZA201607813B (en) 2018-05-30
CN106488931A (zh) 2017-03-08
US20170152304A1 (en) 2017-06-01
JP6649284B2 (ja) 2020-02-19
RU2017102387A (ru) 2018-07-26
AU2015279212A1 (en) 2016-12-01
RU2703903C2 (ru) 2019-10-22
CA2950489C (en) 2022-09-20
CN106488931B (zh) 2021-12-28
US11267871B2 (en) 2022-03-08
EP3160997A1 (en) 2017-05-03
KR20170020423A (ko) 2017-02-22
RU2017102387A3 (ja) 2018-07-26
EP3160997B1 (en) 2020-10-28
WO2015197763A1 (en) 2015-12-30
BR112016030422A2 (pt) 2017-10-24
JP2017520572A (ja) 2017-07-27
CA2950489A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
HK1254310A1 (zh) 抗garp抗體
IL252004B (en) Ether-substituted antibody
IL248802B (en) Antibody formulation
ZA201607813B (en) Topical application for an anti-hsv antibody
IL256099A (en) antibody
IL268889A (en) Anti-EPHA4 antibody
EP3159396A4 (en) Object moving device
IL291164A (en) Anti-nme antibody
GB201515351D0 (en) Antibody
GB201410520D0 (en) Antibody
HK1249549A1 (zh) 抗體
HUE057499T2 (hu) Antitest
GB201600871D0 (en) Antibody
EP3178931A4 (en) Anti-orai1 antibody
EP3279661A4 (en) Immunoassay device
GB201417447D0 (en) Improved immunoassay for pyrrolidinophenones
EP3123277A4 (en) Computing device
EP3127922A4 (en) Anti-chondroitin-sulfate-e antibody
GB201513447D0 (en) Antibody
GB201418776D0 (en) Antibody
GB201413745D0 (en) Antibody
GB201411319D0 (en) Antibody
GB201407535D0 (en) Antibody Drug - Conjugates